Compile Data Set for Download or QSAR
Report error Found 40 Enz. Inhib. hit(s) with all data for entry = 12440
TargetSerine/threonine-protein kinase SIK2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702932(US20240366581, Example 10)
Affinity DataIC50: 1.20nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702934(US20240366581, Example 12)
Affinity DataIC50: 1.70nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702932(US20240366581, Example 10)
Affinity DataIC50: 1.70nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702934(US20240366581, Example 12)
Affinity DataIC50: 2.20nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702928(US20240366581, Example 6)
Affinity DataIC50: 2.5nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702928(US20240366581, Example 6)
Affinity DataIC50: 2.80nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702926(US20240366581, Example 4)
Affinity DataIC50: 3.30nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702926(US20240366581, Example 4)
Affinity DataIC50: 3.40nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702924(6-(5,6-Dimethoxy-benzoimidazol-1-yl)-2-phenylamino...)
Affinity DataIC50: 3.80nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702931(US20240366581, Example 9)
Affinity DataIC50: 6.20nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702933(US20240366581, Example 11)
Affinity DataIC50: 6.30nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702931(US20240366581, Example 9)
Affinity DataIC50: 6.5nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702927(US20240366581, Example 5)
Affinity DataIC50: 7.40nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702925(US20240366581, Example 3)
Affinity DataIC50: 7.80nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702927(US20240366581, Example 5)
Affinity DataIC50: 9.5nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702924(6-(5,6-Dimethoxy-benzoimidazol-1-yl)-2-phenylamino...)
Affinity DataIC50: 14nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702923(US20240366581, Example 1)
Affinity DataIC50: 14.2nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702923(US20240366581, Example 1)
Affinity DataIC50: 15.1nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702925(US20240366581, Example 3)
Affinity DataIC50: 15.5nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702933(US20240366581, Example 11)
Affinity DataIC50: 15.8nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702930(US20240366581, Example 8)
Affinity DataIC50: 16.2nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702929(US20240366581, Example 7)
Affinity DataIC50: 18.2nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702930(US20240366581, Example 8)
Affinity DataIC50: 27.4nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702929(US20240366581, Example 7)
Affinity DataIC50: 29.7nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702928(US20240366581, Example 6)
Affinity DataIC50: 39.9nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702932(US20240366581, Example 10)
Affinity DataIC50: 44.9nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702923(US20240366581, Example 1)
Affinity DataIC50: 57.2nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702934(US20240366581, Example 12)
Affinity DataIC50: 69.2nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702924(6-(5,6-Dimethoxy-benzoimidazol-1-yl)-2-phenylamino...)
Affinity DataIC50: 97.2nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702926(US20240366581, Example 4)
Affinity DataIC50: 114nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702931(US20240366581, Example 9)
Affinity DataIC50: 146nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702925(US20240366581, Example 3)
Affinity DataIC50: 156nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702929(US20240366581, Example 7)
Affinity DataIC50: 188nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702933(US20240366581, Example 11)
Affinity DataIC50: 206nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702930(US20240366581, Example 8)
Affinity DataIC50: 260nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702927(US20240366581, Example 5)
Affinity DataIC50: 331nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702935(US20240366581, Example 13)
Affinity DataIC50: 995nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702936(US20240366581, Example 14)
Affinity DataIC50: 7.48E+3nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702935(US20240366581, Example 13)
Affinity DataIC50: 2.25E+4nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM702935(US20240366581, Example 13)
Affinity DataIC50: 3.00E+4nMAssay Description:In the presence of SIK2 (resp. SIK1 or SIK3) and ATP the CHK-peptide (KKKVSRSGLYRSPSMPENLNRPR with C-terminal arginine amide modification) were phosp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent